Product Releases

Assay Detects Genotoxic Effects of Compounds

Tue, 12/11/2012 - 11:48am


Gentronix BlueScreen HCBlueScreen HC is the latest assay from Gentronix to use genetically modified, human-derived cells to detect the genotoxic effects of compounds. The new assay builds flexibility into the use of GADD45a assays for pharmaceutical, personal care, and consumer product testing. Originally used for theGreenScreen HC assay, p53-competent Human TK6 cells have now been modified to report expression of the GADD45a gene that occurs as a result of genotoxic damage using an alternative reporter construct. Whereas GreenScreen uses fluorescence from Green Fluorescent Protein (GFP) to signal GADD45a expression, the BlueScreen HC assay utilizes a luciferase from the marine copepod Gaussia princeps to generate a luminescent output that delivers both high specificity and high sensitivity, and also helps to reduce problems due to autofluorescence. GADD45a plays an important role in mediating the adaptive response to genotoxic stress. The patented system used in BlueScreen HC and GreenScreen HC incorporates complex regulatory elements to enable a faithful GADD45a response. The assay generates positive results for direct-acting mutagens, clastogens, as well as aneugens, and topoisomerase and polymerase inhibitors. Importantly, correct negative results are produced for non-genotoxic compounds, many of which give misleading positive results in other in vitro genotoxicity tests. A metabolic activation protocol using rodent S9 liver extract extends the range of compounds detected to include genotoxic metabolites. Gentronix Ltd., +44 (0)161 606 7266,


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.